<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025971</url>
  </required_header>
  <id_info>
    <org_study_id>S20131216</org_study_id>
    <nct_id>NCT03025971</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation</brief_title>
  <official_title>Efficacy and Safety Evaluation for The Interventional Aortic Valve Bioprosthesis and Delivery System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation With Elevated Surgical Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JC Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JC Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, nonrandomized, single-arm, controlled target value study,
      designed to include no less than 82 patients in at least two (2) clinical centers in China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of the J-Valve Ausper system for the treatment of
      patients with severe aortic stenosis and/or aortic regurgitation with elevated risk for
      surgery. A prospective, multicenter, nonrandomized, single-arm, controlled target value
      study, designed to include no less than 82 patients in at least two (2) clinical centers in
      China.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac function improvement</measure>
    <time_frame>30 days, 6 months, 12 months and annually up to 5 years</time_frame>
    <description>New York Heart Association (NYHA) Functional class</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Major Adverse Cardiovascular Cerebrovascular Events (MACCE)</measure>
    <time_frame>30 days, 6 months, 12 months and annually up to 5 years</time_frame>
    <description>All-cause mortality, myocardial infarction (Q-wave and non Q-wave), stroke, acute renal damage, major vascular complications, life-threatening bleeding events, or re-operation due to valvular dysfunction (surgical or interventional treatment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Major Adverse Valve Related Events (MAVRE)</measure>
    <time_frame>30 days, 6 months, 12 months and annually up to 5 years</time_frame>
    <description>Valve related deaths, valve related complications, or implantation of a permanent pacemaker or defibrillator within 14 days of operation. Valve related complications include any structural degradation or non-structural dysfunction of the valve prosthesis, thrombosis, embolism, bleeding events, or valve prosthesis endocarditis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Technical Success</measure>
    <time_frame>Within 30 days post procedure</time_frame>
    <description>Implantation of the valve into the precise anatomical position of the native aortic valve.
No valve migration
No positioning errors.
Paravalvular leak is less than moderate (ratio of regurgitation surface area/left ventricular surface area 25-50%).
Successful removal of the entire delivery device.
Implantation of the valve into the precise anatomical position of the native aortic valve.
No valve migration
No positioning errors.
Paravalvular leak is less than moderate (ratio of regurgitation surface area/left ventricular surface area 25-50%).
Successful removal of the entire delivery device.</description>
  </other_outcome>
  <other_outcome>
    <measure>Device Success</measure>
    <time_frame>Within 30 days post procedure</time_frame>
    <description>no intraoperative death,
valve prosthesis has been accurately implanted into the anatomic position of the native aortic valve is performing its anticipated function.
The intended performance of the bioprosthetic valve function:
no mismatch between the valve prosthesis and the patient,
mean transvalvular pressure gradient is ≤20 mmHg or
peak forward aortic blood flow velocity of &lt;3.0 m/s, and no moderate or severe aortic regurgitation</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Aortic Valve Stenosis With Insufficiency</condition>
  <arm_group>
    <arm_group_label>Single arm observational study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>J-Valve Transcatheter Aortic valve replacement</intervention_name>
    <description>Transapical Transcatheter Aortic Valve Replacement</description>
    <arm_group_label>Single arm observational study</arm_group_label>
    <other_name>TAVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent

          2. Age ≥18years of age

          3. Presents with symptomatic aortic stenosis and/or aortic regurgitation, as well as NYHA
             rating of NYHA ≥ II

          4. Has undergone the diagnosis of at least one interventional cardiologist and two
             cardiac surgeons: the patients are contraindicated for traditional open heart valve
             replacement surgery (defined as 30 days post-op mortality risk &gt;50%, irreversible
             complications, or other influential post-operative factors [such as severe
             calcification in the ascending aorta and aortic valve, weak physical condition, chest
             deformities, severe liver diseases, severe lung diseases, etc.] or high risk for
             surgery (LogEuroSCORE≥20% and or STS≥8)

          5. Has a diagnosis from at least one interventional cardiologist and two cardiac surgeons
             that the patient may benefit from a valve implantation

          6. Severe aortic stenosis with electrocardiography results as follows: mean transvalvular
             pressure gradient ≥40 mmHg or maximal forward aortic blood flow velocity of ≥4.0 m/s,
             aortic valve area &lt; 0.8 cm2 (or AVA index &lt; 0.5 cm2/m2); and/or severe aortic
             regurgitation, electrocardiography results show symptomatic moderate regurgitation or
             severe regurgitation

          7. Without severe pulmonary arterial hypertension

          8. The patient is willing to cooperate with all follow-up visits.

             Anatomical Inclusion Criteria:

          9. Aortic annulus &gt;19mm and &lt;29mm, standardized using cardiac CT measurements;

         10. Ascending aortic diameter &lt;50mm at the sinotubular junction.

        Exclusion Criteria:

          1. Patients with infection or who have any sign of infection

          2. Previous history of endocarditis or patients with active endocarditis

          3. Incidence of acute myocardial infarction within the past 30 days (Q-wave MI, or non
             Q-wave MI with creatine kinase, an increase in troponin T)

          4. Any cardiac mass discovered during echocardiography, left ventricular or atrial
             thrombosis

          5. Suffering from uncontrollable atrial fibrillation

          6. Hereditary hypertrophic cardiomyopathy

          7. Mitral or tricuspid valve insufficiency (Class Ⅱ regurgitation or greater)

          8. Has previously undergone aortic valve implantation (mechanical valve or biological
             valve frame)

          9. Is known to be allergic to contrast agents, aspirin, heparin, ticlopidine medications,
             nitinol or porcine products

         10. Is known to be contraindicated for or is allergic to all anti-coagulants or is unable
             to use anti-coagulants during the study

         11. Is known to have one of the following conditions (according to evaluations beginning
             from screening through the day of the procedure):

               -  Other diseases that may reduce the life expectancy to less than 12 months (such
                  as clinically recurrent or metastatic cancer, congestive heart failure, etc.)

               -  Currently has drug abuse problems (such as alcohol, cocaine, heroin, etc.)

               -  Plans to undergo surgery that may result in non-compliance with the study
                  protocol or that may cause confusion in data interpretation.

         12. Has experienced a cerebrovascular accident (CVA) within the last 6 months

         13. Patients suffering from stenosis of the carotid, internal carotid, or vertebral
             arteries (70%)

         14. White cell count ＜3×109/L, platelet count＜50×109/L

         15. Hemoglobin ＜90 g/L

         16. Severely lowered left ventricular function, left ventricular ejection fraction &lt; 20 %

         17. Aortic aneurysm in the abdomen or chest

         18. Hepatic encephalopathy or acute active hepatitis

         19. Currently undergoing dialysis or baseline creatine levels &gt;2.5 mg/dL (221μmoI/L)

         20. Prone to bleeding, has a history of clotting disorders or refuses blood transfusions

         21. Active ulcer or active gastrointestinal (GI) bleeding

         22. Suffering from nervous system diseases that severely influence the patients' ability
             to move or to perform daily activities

         23. Patients with severe dementia

         24. Any reason for emergent surgery

         25. Taking part in other clinical trials for pharmaceuticals or medical devices

         26. Those who are pregnant, plan to become pregnant, or who are taking estrogen or
             estrogen-like drugs (women suspected of being pregnant must test negative on a urine
             pregnancy test or for chorionic gonadotropin serum).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Zhang, MD</last_name>
    <role>Study Director</role>
    <affiliation>CEO, President</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Aortic Stenosis and/or severe aortic regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

